Ishara Investments LP Makes New Investment in Silence Therapeutics PLC Sponsored ADR $SLN

Ishara Investments LP purchased a new position in shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 240,000 shares of the company’s stock, valued at approximately $1,459,000. Silence Therapeutics comprises about 1.7% of Ishara Investments LP’s holdings, making the stock its 20th biggest holding.

A number of other institutional investors also recently bought and sold shares of SLN. Nantahala Capital Management LLC raised its position in Silence Therapeutics by 48.0% during the 4th quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company’s stock worth $9,378,000 after buying an additional 500,000 shares during the last quarter. Millennium Management LLC raised its position in Silence Therapeutics by 50.3% during the 3rd quarter. Millennium Management LLC now owns 298,512 shares of the company’s stock worth $1,549,000 after buying an additional 99,865 shares during the last quarter. UBS Group AG raised its position in Silence Therapeutics by 34.5% during the 3rd quarter. UBS Group AG now owns 307,363 shares of the company’s stock worth $1,595,000 after buying an additional 78,854 shares during the last quarter. Marshall Wace LLP raised its position in Silence Therapeutics by 87.1% during the 4th quarter. Marshall Wace LLP now owns 155,680 shares of the company’s stock worth $947,000 after buying an additional 72,461 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in Silence Therapeutics during the 4th quarter worth approximately $177,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Jefferies Financial Group raised shares of Silence Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a research report on Wednesday. Finally, William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Silence Therapeutics Price Performance

Shares of NASDAQ SLN opened at $6.76 on Thursday. The stock has a market capitalization of $319.34 million, a price-to-earnings ratio of -4.25 and a beta of 1.48. Silence Therapeutics PLC Sponsored ADR has a 12 month low of $4.19 and a 12 month high of $8.40. The firm’s 50 day simple moving average is $6.76 and its 200-day simple moving average is $6.10.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.14). The firm had revenue of $0.42 million for the quarter, compared to analyst estimates of $1.26 million. Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%. Analysts anticipate that Silence Therapeutics PLC Sponsored ADR will post -0.95 earnings per share for the current fiscal year.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.